MX2022011364A - Heteromultímeros de actriia y actriib de un solo brazo y metodos para el tratamiento de enfermedades o condiciones renales. - Google Patents

Heteromultímeros de actriia y actriib de un solo brazo y metodos para el tratamiento de enfermedades o condiciones renales.

Info

Publication number
MX2022011364A
MX2022011364A MX2022011364A MX2022011364A MX2022011364A MX 2022011364 A MX2022011364 A MX 2022011364A MX 2022011364 A MX2022011364 A MX 2022011364A MX 2022011364 A MX2022011364 A MX 2022011364A MX 2022011364 A MX2022011364 A MX 2022011364A
Authority
MX
Mexico
Prior art keywords
arm
conditions
methods
heteromultimers
actriia
Prior art date
Application number
MX2022011364A
Other languages
English (en)
Inventor
Ravindra Kumar
Gang Li
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MX2022011364A publication Critical patent/MX2022011364A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

En algunos aspectos, la descripción se refiere a heteromultímeros de ActRIIA de un solo brazo y heteromultímeros de ActRIIB de un solo brazo y a métodos para usar dichos heteromultímeros para tratar, prevenir o reducir la tasa de progresión y/o la gravedad de las enfermedades o afecciones renales, particularmente para tratar, prevenir o reducir la tasa de progresión y/o la gravedad de una o más complicaciones asociadas con el riñón. La descripción también proporciona métodos para usar un heteromultímero de ActRIIA de un solo brazo o heteromultímero de ActRIIB de un solo brazo para tratar, prevenir o reducir la velocidad de progresión y/o gravedad de una variedad de afecciones que incluyen, de modo no taxativo, síndrome de Alport, glomeruloesclerosis focal segmentaria (FSGS), enfermedad renal poliquística y/o enfermedad renal crónica.
MX2022011364A 2020-03-13 2021-03-11 Heteromultímeros de actriia y actriib de un solo brazo y metodos para el tratamiento de enfermedades o condiciones renales. MX2022011364A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062989037P 2020-03-13 2020-03-13
PCT/US2021/021991 WO2021183819A1 (en) 2020-03-13 2021-03-11 Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions

Publications (1)

Publication Number Publication Date
MX2022011364A true MX2022011364A (es) 2022-11-30

Family

ID=77672098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011364A MX2022011364A (es) 2020-03-13 2021-03-11 Heteromultímeros de actriia y actriib de un solo brazo y metodos para el tratamiento de enfermedades o condiciones renales.

Country Status (10)

Country Link
US (1) US20230134083A1 (es)
EP (1) EP4117707A1 (es)
JP (1) JP2023528117A (es)
KR (1) KR20230002391A (es)
CN (1) CN115515618A (es)
AU (1) AU2021236249A1 (es)
BR (1) BR112022018319A2 (es)
CA (1) CA3171638A1 (es)
MX (1) MX2022011364A (es)
WO (1) WO2021183819A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117137924A (zh) * 2023-09-28 2023-12-01 宜兴食品与生物技术研究院有限公司 N-乙酰-d-甘露糖胺在制备促进骨生长的食品及药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53883A (fr) * 2015-04-06 2021-08-18 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
BR112017021510A2 (pt) * 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
CN116650622A (zh) * 2016-10-05 2023-08-29 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
EP3522913A4 (en) * 2016-10-05 2020-10-28 Acceleron Pharma Inc. ALK4: ACTRIIB HETEROMULTIMERS AND USES THEREOF

Also Published As

Publication number Publication date
CA3171638A1 (en) 2021-09-16
KR20230002391A (ko) 2023-01-05
EP4117707A1 (en) 2023-01-18
CN115515618A (zh) 2022-12-23
BR112022018319A2 (pt) 2022-11-22
AU2021236249A1 (en) 2022-10-06
WO2021183819A1 (en) 2021-09-16
JP2023528117A (ja) 2023-07-04
US20230134083A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
MX2022011364A (es) Heteromultímeros de actriia y actriib de un solo brazo y metodos para el tratamiento de enfermedades o condiciones renales.
MX2018009498A (es) Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1.
WO2007037985A3 (en) Systems and methods for treating water
AR063314A2 (es) Metodos para purificar preparados de virus
WO2016187217A3 (en) Methods and compositions for treating aging-associated impairments
WO2007021612A3 (en) Contact lens extraction/hydration systems and methods of reprocessing fluids used therein
WO2007018854A3 (en) System and method of slurry treatment
WO2010076400A8 (fr) Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome intraoculaire primitif
MX2019009377A (es) Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
EA201891405A1 (ru) Стеклянная подложка для химического упрочнения и способ химического упрочнения с контролируемой кривизной
WO2023022968A3 (en) Compositions and methods for treating renal diseases or conditions
CA3134361A1 (en) Method for processing plastic waste pyrolysis gas
WO2019016247A3 (en) Agents, uses and methods for treatment
MX2019012256A (es) Almidones pregelatinizados que tienen una alta tolerancia al proceso y metodos para fabricar y usar los mismos.
NO20060930L (no) Vandig suspensjon av magnesiumholdig kalk og fremgangsmate ved dens fremstilling
WO2008061007A3 (en) Improving the transfer of slurry in a bayer process
WO2020182862A3 (de) Verfahren zum enthärten von trinkwasser, schwimm- und badebeckenwasser und/oder prozesswasser
MX2022016237A (es) Proteinas actrii para el tratamiento de la hipertension arterial pulmonar (hap).
WO2007134064A3 (en) Method and apparatus for removing impurities in rejects from sequential filters using separate treatment units
MX2021000976A (es) Compuestos para usarse en el tratamiento de trastornos renales.
MX2018009628A (es) Sistema para limpiar una superficie de vidrio de un vehiculo.
EP4215494A4 (en) SEPARATION TOWER AND METHOD FOR TREATING CONDENSATE WATER
WO2019083201A3 (ko) 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도
CN208896788U (zh) 一种轮胎胎面花纹结构
WO2008107098A3 (de) Vorrichtung zur enthärtung von rohwasser